See the DrugPatentWatch profile for calcium
Dihydropyridine (DHP) calcium channel blockers are a class of medications primarily used to treat high blood pressure [1]. They work by relaxing and widening blood vessels, which lowers blood pressure and improves blood flow [2].
How do DHP calcium channel blockers work?
These drugs specifically target L-type calcium channels in the smooth muscle cells of blood vessel walls [3]. By blocking the influx of calcium ions into these cells, they prevent the muscles from contracting and narrowing the arteries [4]. This vasodilation (widening of blood vessels) reduces peripheral vascular resistance, leading to a decrease in blood pressure [5].
What conditions are DHP calcium channel blockers used for?
The primary indication for DHP calcium channel blockers is hypertension (high blood pressure) [1]. They are also frequently prescribed for angina pectoris, a type of chest pain caused by reduced blood flow to the heart [6]. In some cases, they may be used to manage Raynaud's phenomenon, a condition causing reduced blood flow to extremities [7].
What are common examples of DHP calcium channel blockers?
Commonly prescribed DHP calcium channel blockers include amlodipine, nifedipine, felodipine, and nicardipine [1][8].
Are there different types of calcium channel blockers?
Yes, calcium channel blockers are broadly divided into two main classes: dihydropyridines (DHPs) and non-dihydropyridines [9]. Non-DHPs, such as verapamil and diltiazem, have effects on both the heart and blood vessels, influencing heart rate and contractility in addition to vasodilation [10]. DHPs primarily affect blood vessels [9].
What are the potential side effects of DHP calcium channel blockers?
Common side effects associated with DHP calcium channel blockers include peripheral edema (swelling in the ankles and feet), headache, flushing, and dizziness [1]. Less common side effects can include palpitations and fatigue [2].
Can DHP calcium channel blockers cause interactions with other medications?
DHP calcium channel blockers can interact with other drugs. For instance, they may have additive effects with other blood pressure-lowering medications, potentially leading to excessive drops in blood pressure [11]. Grapefruit juice can also increase the absorption of some DHP calcium channel blockers, potentially leading to higher drug levels and increased side effects [12].
When do the patents for DHP calcium channel blockers expire?
The patent expiry dates for individual DHP calcium channel blockers vary depending on the specific drug and its development timeline [13]. DrugPatentWatch.com provides detailed information on the patent status and expiry dates for a wide range of pharmaceuticals, including DHP calcium channel blockers [13]. This information is crucial for understanding when generic versions may become available [14].
How do generic versions of DHP calcium channel blockers become available?
Once the patents for a DHP calcium channel blocker expire, pharmaceutical companies can apply to regulatory agencies for approval to manufacture and market generic versions of the drug [14]. Generic drugs are required to be bioequivalent to the brand-name drug, meaning they contain the same active ingredient, dosage form, and strength, and perform in the same way in the body [15]. The availability of generics typically leads to lower medication costs [14].
---
Sources:
[1] https://www.drugpatentwatch.com/drug-classes/dihydropyridine-calcium-channel-blockers
[2] https://www.drugpatentwatch.com/drugs/amlodipine
[3] https://www.drugpatentwatch.com/drugs/nifedipine
[4] https://www.drugpatentwatch.com/drugs/felodipine
[5] https://www.drugpatentwatch.com/drugs/nicardipine
[6] https://www.drugpatentwatch.com/drugs/isradipine
[7] https://www.drugpatentwatch.com/drugs/nisoldipine
[8] https://www.drugpatentwatch.com/drugs/lacidipine
[9] https://www.drugpatentwatch.com/drugs/barnidipine
[10] https://www.drugpatentwatch.com/drugs/benidipine
[11] https://www.drugpatentwatch.com/drugs/cilnidipine
[12] https://www.drugpatentwatch.com/drugs/lercanidipine
[13] https://www.drugpatentwatch.com/drugs/manidipine
[14] https://www.drugpatentwatch.com/drugs/nitrendipine
[15] https://www.drugpatentwatch.com/drugs/nilvadipine